Nuzeniec

This startup develops non-invasive diagnostic technology for dry eye syndrome. Their imaging test uses an advanced algorithm to detect Demodex mites in patients' eyes, providing healthcare practitioners with an efficient and accessible diagnostic tool to improve treatment.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Diagnosing Demodex mites, a common cause of blepharitis and other eye conditions, traditionally requires invasive and time-consuming microscopic evaluation of epilated eyelashes. This process can be uncomfortable for patients and inefficient for practitioners, leading to delays in diagnosis and treatment.

Solution

Demox provides a rapid, non-invasive imaging test that leverages a smartphone camera and a proprietary algorithm to detect the presence of Demodex mites on a patient's eyelashes. The Demox Scan application guides clinicians through the image capture process, then analyzes the image in real-time to identify Demodex with high accuracy. Results are available within minutes, enabling immediate treatment decisions and improved patient outcomes. The test is safe, simple to administer, and can be performed in virtually any clinical setting, streamlining the diagnostic workflow for Demodex-related eye conditions.

Target Audience

The primary target audience includes ophthalmologists, optometrists, general practitioners, and opticians seeking a rapid and non-invasive method for Demodex diagnosis, as well as patients experiencing symptoms of blepharitis or other Demodex-related eye conditions.

Features

Smartphone-based application for image capture and analysis
Proprietary image-recognition algorithm for Demodex detection
Non-invasive procedure, eliminating the need for epilation
Rapid results in 3-5 minutes
High accuracy (97-98%)
Suitable for use by ophthalmologists, optometrists, general practitioners, and opticians